1-3 of 3
J. Gerecitano
Close
Sort by
Journal Articles

A Phase I/II Trial of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 Dosed Q14D without and with Prophylactic G-CSF in Non-Hodgkin (NHL) or Hodgkin Lymphoma (HL).

Owen A O'Connor, J. Gerecitano, H. Van Deventer, B. Afanasyev, J. Hainsworth, M. Chen, K. Saikali, J. Seroogy, R. Escandon, A. Wolff, MG. Conlan
Journal: Blood
Blood (2009) 114 (22): 1673.
https://doi.org/10.1182/blood.V114.22.1673.1673
Published: 2009
Journal Articles

Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies.

Wyndham H Wilson, MD, PhD, O. O’Connor, M.D., Myron S. Czuczman, MD, Ann LaCasce, MD, J. Gerecitano, M.D., Ph.D., John P. Leonard, MD, Anil Tulpule, MD, Hao Xiong, Ph.D., Yi-Lin Chiu, Ph.D., Todd Busman, Ph.D., Raymond A. Knight, MBA, Sari Enschede, M.D., Andrew Krivoshik, M.D., Ph.D., Rod Humerickhouse, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 2108.
https://doi.org/10.1182/blood.V112.11.2108.2108
Published: 2008
Journal Articles

Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience.

Owen A. O’Connor, MD, PhD, P.A. Hamlin, MD, J. Gerecitano, MD, PhD, C.S Portlock, MD, A. Noy, MD, C. Moskowitz, MD, D.J. Straus, MD, D. Sarasohn, MD, O. Dumetrescu, MD, J. Pappanicolou, RN, E. Neylon, A.D. Zelenetz, MD, M.E. Saunders, MD, D.R. Mould, PhD, M. Fleischer, PhD, F. Sirotnak, PhD, S.M. Horwitz, MD
Journal: Blood
Blood (2006) 108 (11): 400.
https://doi.org/10.1182/blood.V108.11.400.400
Published: 2006